Immunome Ownership | Who Owns Immunome?

Overview Forecast RevenueFinancials Chart

Immunome Ownership Summary

Immunome is owned by 105.01% institutional investors, 9.45% insiders. Blackrock is the largest institutional shareholder, holding 36.46% of IMNM shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 3.90% of its assets in Immunome shares.

IMNM Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Immunome	105.01%	9.45%	-14.46%
Sector	Healthcare Stocks	42.50%	10.81%	46.69%
Industry	Biotech Stocks	45.24%	10.75%	44.01%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	3.76M	36.46%	$45.48M
Fmr	13.06M	15.01%	$152.89M
T. rowe price investment management	8.42M	9.67%	$98.58M
Blackrock funding, inc. /de	5.82M	6.69%	$68.18M
Redmile group	5.02M	5.77%	$58.82M
Janus henderson group	3.46M	5.74%	$36.73M
Vanguard group	4.89M	5.62%	$57.30M
Point72 asset management	4.82M	5.54%	$56.49M
Enavate sciences gp	4.77M	5.48%	$55.84M
Ecor1 capital	4.08M	4.69%	$47.77M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Enavate sciences gp	4.77M	17.05%	$55.84M
Redmile group	5.02M	5.72%	$58.82M
Opaleye management	3.19M	5.27%	$37.30M
Pivotal bioventure partners investment advisor	502.51K	3.40%	$5.88M
Ecor1 capital	4.08M	2.29%	$47.77M
Birchview capital, lp	105.00K	0.93%	$1.23M
Nan fung trinity (hk)	592.10K	0.69%	$6.93M
Readystate asset management lp	1.32M	0.66%	$15.44M
Parkman healthcare partners	351.13K	0.43%	$4.11M
Sphera funds management	147.20K	0.36%	$1.72M

Top Buyers

Holder	Shares	% Assets	Change
Fmr	13.06M	0.01%	6.89M
Blackrock	3.76M	0.00%	2.93M
Morgan stanley	1.83M	0.00%	1.43M
Caption management	1.04M	0.10%	1.04M
Principal financial group	1.10M	0.01%	762.15K

Top Sellers

Holder	Shares	% Assets	Change
Toronto dominion bank	1.04M	0.02%	-1.05M
Vestal point capital, lp	-	-	-1.00M
Avidity partners management lp	-	-	-873.89K
Brown advisory	-	-	-860.78K
Adage capital partners gp	-	-	-775.00K

New Positions

Holder	Shares	% Assets	Change	Value
Pivotal bioventure partners investment advisor	502.51K	3.40%	502.51K	$5.88M
Parkman healthcare partners	351.13K	0.43%	351.13K	$4.11M
Axa investment managers	180.06K	0.01%	180.06K	$2.11M
Millennium management	158.43K	0.00%	158.43K	$1.68M
Sphera funds management	147.20K	0.36%	147.20K	$1.72M

Sold Out

Holder	Change
National bank of canada /fi/	-1.00
Eversource wealth advisors	-8.00
Us bancorp \de\	-21.00
Lindbrook capital	-38.00
Stephens consulting	-50.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Sep 30, 2025	160	8.11%	91,368,868	15.03%	105	1.26%	91	7.06%	37	-
Jun 30, 2025	148	0.68%	79,432,018	9.01%	91	1.08%	85	-20.56%	37	105.56%
Mar 31, 2025	147	18.55%	76,924,342	44.29%	96	1.24%	108	54.29%	17	-51.43%
Dec 31, 2024	123	1.65%	53,309,287	3.16%	88	1.20%	69	4.55%	35	25.00%
Sep 30, 2024	121	5.22%	51,674,695	8.14%	85	1.35%	66	-13.16%	28	27.27%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Growth Compy Commingled Pl S	3.39M	3.90%	555.43K
T. Rowe Price Small-Cap Stock	3.12M	3.58%	84.15K
T. Rowe Price US Small-Cap Core Equity	3.03M	3.49%	182.97K
PRIMECAP Odyssey Aggressive Growth	2.68M	3.08%	-400.90K
Fidelity Growth Compy Commingled Pl O	1.79M	2.97%	-
Fidelity Growth Company Fund	2.38M	2.74%	405.69K
Vanguard Total Stock Mkt Idx Inv	2.19M	2.52%	-48.70K
T. Rowe Price Health Sciences	2.16M	2.48%	-24.26K
iShares Russell 2000 ETF	1.78M	2.05%	-
Vanguard US Total Market Shares ETF	1.64M	1.88%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 03, 2025	BIENAIME JEAN JACQUES	-	Buy	$46.90K
Mar 25, 2025	BIENAIME JEAN JACQUES	-	Buy	$60.68K
Mar 26, 2025	SIEGALL CLAY B	President and CEO	Buy	$999.46K
Mar 24, 2025	BIENAIME JEAN JACQUES	-	Buy	$57.47K
Mar 24, 2025	Tsai Philip	Chief Technology Officer	Buy	$103.57K

Insider Transactions Trends

Date	Buy	Sell
2025 Q3	-	-
2025 Q2	1	-
2025 Q1	5	-
2024 Q4	4	-
2024 Q3	1	2

IMNM Ownership FAQ

Who Owns Immunome?

Immunome shareholders are primarily institutional investors at 105.01%, followed by 9.45% insiders and -14.46% retail investors. The average institutional ownership in Immunome's industry, Biotech Stocks , is 45.24%, which Immunome exceeds.

Who owns the most shares of Immunome?

Immunome’s largest shareholders are Blackrock (3.76M shares, 36.46%), Fmr (13.06M shares, 15.01%), and T. rowe price investment management (8.42M shares, 9.67%). Together, they hold 61.14% of Immunome’s total shares outstanding.

Does Blackrock own Immunome?

Yes, BlackRock owns 36.46% of Immunome, totaling 3.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 45.48M$. In the last quarter, BlackRock increased its holdings by 2.93M shares, a 353.41% change.

Who is Immunome’s biggest shareholder by percentage of total assets invested?

Enavate sciences gp is Immunome’s biggest shareholder by percentage of total assets invested, with 17.05% of its assets in 4.77M Immunome shares, valued at 55.84M$.

Who is the top mutual fund holder of Immunome shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Immunome shares, with 3.90% of its total shares outstanding invested in 3.39M Immunome shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools